in vivo News and Research

RSS

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

Enzon Pharmaceuticals, Inc. today announced the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the Company's novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.

5 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Collagen Matrix's new Collagen Dental Membrane granted FDA 510(k) clearance

Collagen Matrix, Inc., the leader in collagen- and mineral-based matrix engineering, announced today that it has received FDA's 510(k) clearance of a new Collagen Dental Membrane derived from porcine dermis indicated for use in oral surgical procedures involving guided tissue and bone regeneration.

1 Oct 2010

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies.

30 Sep 2010

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Bbiotechnology company NEUROKIN, dedicated to the development of neuroprotective drugs to treat acute neurological diseases, announces today that the European Patent Office (EPO) has granted patent EP 1998778 protecting the use of NK-102, its most advanced drug candidate. This first European award constitutes an important milestone for NEUROKIN. An application for registration is under way in Brazil, Canada, China, USA and Japan.

29 Sep 2010

Crescendo Biologics successfully delivers triple knockout mice

Crescendo Biologics Limited today announces it has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. The proprietary 'triple knockout' mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

29 Sep 2010

c-Met could be a potential personalized target for metastatic HCC

Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

29 Sep 2010

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD- at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii.

28 Sep 2010

Immune-mediated disturbances of neurons contribute to MS: Research

Researchers in Germany have gained new insight into how the immune system causes damage associated with multiple sclerosis (MS), an incurable neuroinflammatory disorder.

24 Sep 2010

Advitech completes UVA testing study on oleosome sunscreen formulation

Advitech Inc. is pleased to announce today that a key UVA testing study has been completed on its oleosome-based sunscreen prototype formulation.

24 Sep 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that the National Cancer Institute has purchased Caliper's Quantum FX, a stand-alone microCT system for pre-clinical imaging, to study spontaneous tumor models in lung cancer.

23 Sep 2010

Miltenyi Biotec releases ACSA-1 MicroBead Kit to isolate GLAST-expressing astrocytes

Miltenyi Biotec announces the worldwide first and exclusive release of the Anti-GLAST (ACSA-1) MicroBead Kit. Isolation of viable GLAST-expressing astrocytes is now possible within one hour using the first commercially available antibody against an extracellular surface epitope of GLAST.

23 Sep 2010

Scientists develop new therapy for treatment of skin, lung cancer

Scientists at the University of Granada have developed a new therapy for the treatment of skin and lung cancer. This therapy involves the use of a suicide coliphage-gene (gene E) that can induce death to cells transfected with it.. Their studies have demostrated that this technique is not only effective in vitro (using tumour cell cultures), but also in vivo through the use of experimental animals in which tumours were induced.

22 Sep 2010

ART closes new $8.5 million venture financing round

Arterial Remodeling Technologies ("ART") announced today that it has closed on a new venture financing round of $8.5 million from existing investors Matignon Technologies and Amundi Private Equity Funds, along with new investor InnoBio Fund managed by CDC Entreprises. Total investment in the Company is now $17 million.

22 Sep 2010

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the Phase I clinical study assessing Inovio's PENNVAX-B DNA vaccine delivered using its proprietary electroporation technology in a preventive setting has fully completed the enrollment of 48 healthy volunteers. The multi-center study is being conducted by Inovio's clinical collaborator, the HIV Vaccine Trials Network (HVTN), at several clinical sites under a protocol designated HVTN-080.

21 Sep 2010

FDA approves Medtronic's Integrity Coronary Stent System

Delivering another innovation for interventional cardiology, Medtronic, Inc.,announced today the U.S. Food and Drug Administration (FDA) approval of the Integrity Coronary Stent System. The new platform for Medtronic's coronary stents, including the Integrity bare-metal stent, is based on an advance in biomedical engineering called continuous sinusoid technology that enables the exploration of other breakthrough device concepts such as a polymer free drug filled stent.

21 Sep 2010

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Athersys, Inc. announced today the publication of a key study in the October issue of Experimental Neurology conducted by researchers at Athersys, the University of Texas Medical School, the Michael E. DeBakey Institute for Comparative Cardiovascular Science and Biomedical Devices, and Texas A&M University.

20 Sep 2010

Transcatheter Technologies implants transapical aortic valve in acute porcine model

Transcatheter Technologies GmbH (TT), an innovative medical device company that is developing a second-generation transcatheter aortic valve prosthesis, announced today that its proprietary transapical aortic valve has been successfully implanted in the acute porcine model.

17 Sep 2010

in vivo News and Research

Preclinical data of Enzon's PEG-SN38 in pediatric neuroblastoma published in Clinical Cancer Research

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

NIH to award $64M under Transformative Research Projects program

Collagen Matrix's new Collagen Dental Membrane granted FDA 510(k) clearance

Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapies

NEUROKIN accentuates its leadership in the treatment of acute neurological diseases

Crescendo Biologics successfully delivers triple knockout mice

c-Met could be a potential personalized target for metastatic HCC

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Immune-mediated disturbances of neurons contribute to MS: Research

Advitech completes UVA testing study on oleosome sunscreen formulation

Tolerx presents otelixizumab preclinical research at 46th EASD

NCI selects Caliper's Quantum FX microCT system to study tumor models in lung cancer

Miltenyi Biotec releases ACSA-1 MicroBead Kit to isolate GLAST-expressing astrocytes

Scientists develop new therapy for treatment of skin, lung cancer

ART closes new $8.5 million venture financing round

Inovio Pharmaceuticals completes enrollment for PENNVAX-B vaccine Phase I clinical study

FDA approves Medtronic's Integrity Coronary Stent System

MultiStem multipotent adult progenitor cell therapy preserves 'blood brain barrier'

Transcatheter Technologies implants transapical aortic valve in acute porcine model

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News